U.S. stock market midday update: Abpro down 14% with increased trading volume, market sentiment fluctuates significantly, future trends need to be monitored

U.S. Stock Market Midday Update Abpro, down 14.00%, with increased trading volume and no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks with High Trading Volume in the Industry AbbVie up 0.49%. Based on recent key news: On February 16, market analysis showed that although AbbVie was rated as a moderate buy, top analysts believe there are other stocks more worthy of investment. This rating may have affected investor confidence, leading to stock price fluctuations. On February 15, the analyst team at Motley Fool recommended other stocks as preferred long-term investments, and AbbVie was not on the recommendation list. This may have led some investors to reassess their portfolios, impacting the stock price. On February 15, analysts pointed out that AbbVie remains a top choice for long-term income investors, especially after the recent stock price decline. This view may have attracted some investors, pushing the stock price up. The pharmaceutical industry has shown stable performance recently, with significant capital inflow. Gilead Sciences down 0.37%. Based on recent key news: On February 18, Gilead Sciences announced the acquisition of global exclusive rights to Genhouse Bio's MAT2A inhibitor GH31 for $80 million. This move aims to expand its oncology product line and may have a positive impact on the stock price. Source: Business Wire On February 17, Gilead Sciences released safety information regarding Yeztugo, emphasizing precautions for its use in undiagnosed HIV-1 infections. This information may raise market concerns about the safety of its products. Source: Business Wire On February 16, MarketsandMarkets™ launched an AI-driven sales intelligence tool to help businesses identify market opportunities. Although not directly related to Gilead Sciences, it shows market interest in innovative technologies. Source: MarketsandMarkets™ The competition in the oncology treatment field is intensifying, and policy changes need to be monitored. Forty Pharmaceuticals down 3.40%. Based on recent key news: On February 16, Cornerstone Pharmaceuticals announced that its core asset CS2009's Phase II clinical trial application received FDA approval. This news has driven market attention towards the biopharmaceutical industry, which may impact Forty Pharmaceuticals' stock price. On February 17, Deciphera Pharmaceuticals announced that the FDA accepted its new drug application, and the market's optimistic sentiment towards new drug development may affect Forty Pharmaceuticals. On February 17, Newron Pharmaceuticals received funding support to advance its Phase III project, showing a positive trend in capital flow within the industry, which may impact Forty Pharmaceuticals' market performance. The biopharmaceutical industry has recently received policy support, with significant capital inflow Stocks Ranked Among the Top by Market Capitalization in the Industry Amgen rose by 0.83%. Amgen rose by 0.83%. There have been no significant news recently; trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. no_news